News
-
-
PRESS RELEASE
Lumibird: FY revenue of EUR 225.6 million (+10.2% at constant scope and exchange rates)
LUMIBIRD Group achieves FY revenue of €225.6 million, up 10.2% at constant scope and exchange rates. Photonics division shows strong growth. Medical division sales stable reflecting resilient activity. 2025 EBITDA margin expected over 19% -
-
PRESS RELEASE
VALBIOTIS SA: Valbiotis launches an exclusive commercial benefit for its shareholders: a 20% discount on ValbiotisPRO® and ValbiotisPLUS® ranges
Valbiotis launches a 20% discount on ValbiotisPRO® and ValbiotisPLUS® ranges exclusively for its shareholders, strengthening the link with them and rewarding their commitment -
-
REGULATED PRESS RELEASE
Disclosure of transactions in own shares from January 19 to January 23, 2026
-
-
-
-